• Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Menu
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Search
Close

Dp2

Polypill plus aspirin prevents primary CVD events in people at medium risk (TIPS-3).

  • View Spotlight

Increasing
knowledge &
understanding
of aspirin

Increasing knowledge & understanding of aspirin

Founded in 1974, the International Aspirin Foundation shares
information and stimulates research interest and discussion about
all aspects of aspirin and acetylsalicylic acid.

Founded in 1974, the International Aspirin Foundation shares information and stimulates research interest and discussion about all aspects of aspirin and acetylsalicylic acid.

Read More

Scientific Advisory Board

Multidisciplinary expertise

Our Scientific Advisory Board brings together international experts from different backgrounds including pharmacology, neurology, gastroenterology, oncology and cardiology. Their multidisciplinary expertise is hugely valuable and guides all our activity.
More About SAB

Key Features

Scientific information

Guidelines

A working list of international guidelines with information on aspirin use
View guidelines

Disease Prevention

Information on aspirin use in disease prevention, including chronic; cardiovascular; cancer and heart disease
Learn more

Aspirin Summaries

Keep up to date with our written summaries of the latest aspirin related research
Read summaries

Aspirin Matters

Our Podcasts let you hear from world leading experts on all things Aspirin
Discover podcasts

Biennial Awards

Celebrating excellence

Established in 1992, our scientific awards recognise and celebrate meaningful biomedical research into aspirin and its effects on human health. Two separate awards are open to senior and early career scientists.
Find out more

Scientific Conference

Sharing insight

Our biennial conference is a great opportunity to hear from leading experts reviewing basic science and clinical implications across a range of topics. By coming together to discuss the latest international data, we can enhance understanding, build stronger networks and inspire new ideas.
More information

Join the Conversation

Tweets by Aspirin1897

@Aspirin1897

View our profile

Spotlight

News
Forum
Events
Video
Podcast
News
Dp2

Polypill plus aspirin prevents primary CVD events in people at medium risk (TIPS-3)

This multicentre, 2-by-2-by-2 factorial study randomised 5713 participants with medium cardiovascular disease (CVD) risk to receive a polypill (containing a statin and three blood pressure

Read More
Forum

Share with colleagues

Contributions from the research community shared here are unsolicited and are not peer reviewed. We encourage sharing information and stimulating research interest, but we do not endorse or approve the submission. See full disclaimer

Want to contribute?
Aspirin and COVID-19 – comment from Professor Mazzeffi, Maryland, USA

Professor Mazzeffi.

Full Article
Targeted aspirin cancer chemoprevention strategies

David A. Drew, PhD.

Full Article
Aspirin and COVID-19

Maikel Peppelenbosch.

Full Article

Events

Science Award Ceremony

This virtual event celebrated the work of Professors Lars Wallentin, Bo Norrving, Jan van Gijn and Tom Meade, the scientists who led four pivotal low-dose aspirin trials, which ultimately contributed to the prevention of countless coronary and cardiovascular events worldwide.

Previous Awards

Video

Professor Bo Norrving

Prof Norrving reflects on the Swedish Low-dose Aspirin Trial (SALT), expanding on the data findings over four decades, giving an up to date  perspective on the secondary prevention of low dose aspirin in stroke.  Prof Norrving makes the point that this basic therapy should be globally available as recommended by the World Health Organisation.

Podcast

Hear from the experts.

Aspirin Matters with Professor J Michael Gaziano 

Part 2 – Professor Gaziano discusses recent aspirin primary prevention trials and their impact on clinical practice today.

In the second part of this podcast Professor Gaziano explains the complexities of designing and delivering primary aspirin CVD prevention trials. He puts context around the ASCEND, ASPREE and ARRIVE trials and the questions they were set up to answer. Mike also explores and contextualises the risk of gastrointestinal bleeding versus aspirin’s primary prevention benefit in people at different risk stratifications. Consideration of other benefits such as colorectal cancer prevention is included. Ways to improve the risk benefit ratio are discussed including the place for gastroprotectants. Aspirin is one way to reduce CVD risk and is particularly important in people unable to lower their risk through other strategies. In the podcast Professor Gaziano explains why he feels aspirin still has an important primary CVD prevention role and should be considered in the right patients with the right monitoring and discussion.
Discover Podcasts

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

Footer Logo
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
Menu
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
Twitter
Linkedin

Copyright © 2020 Aspirin Foundation

Website by mtc.

Have something to say about aspirin?

We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.

Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Rothwell

    Peter Rothwell

    PAST – CHAIR
    Name

    Peter M. Rothwell PhD, MD, FRCP, FMedSci

    Academic Affiliations:
    • Action Research Chair of Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford;
    • Founding Director, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford;
    • Wellcome Trust Senior Investigator;
    • Emeritus NIHR Senior Investigator;
    • Theme Leader, Stroke and Vascular Dementia, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford
    Discipline:
    Neurology and Stroke Medicine
    Scientific Interests:
    • Risks and benefits of aspirin;
    • Primary and secondary prevention of stroke;
    • Effects of blood pressure on the brain.
    Declaration of Conflicts of Interest:
    I received consultant and speakers fees from Bayer AG.
    Return to Scientific Advisory Board

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board